Meritage Portfolio Management Takes Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Meritage Portfolio Management acquired a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 19,776 shares of the specialty pharmaceutical company’s stock, valued at approximately $764,000.

Other institutional investors have also added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new stake in Collegium Pharmaceutical during the second quarter valued at approximately $32,000. nVerses Capital LLC boosted its stake in Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,600 shares in the last quarter. GAMMA Investing LLC increased its position in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares in the last quarter. CWM LLC increased its holdings in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 736 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC acquired a new stake in Collegium Pharmaceutical during the 1st quarter worth about $204,000.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at $4,602,166.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the sale, the executive vice president now directly owns 53,816 shares in the company, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Truist Financial lifted their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. HC Wainwright boosted their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Trading Down 7.3 %

NASDAQ COLL opened at $32.16 on Monday. Collegium Pharmaceutical, Inc. has a one year low of $23.44 and a one year high of $42.29. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11. The company has a 50-day simple moving average of $37.07 and a 200-day simple moving average of $35.21. The firm has a market capitalization of $1.04 billion, a PE ratio of 13.86 and a beta of 0.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.40 by $0.22. The firm had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. Collegium Pharmaceutical’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.13 earnings per share. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.81 earnings per share for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.